Latest Intelligence in South and Central America

Published within

« | ... | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | ... | » »|

Type Product title / description Pub Price
ResearchWire
ResearchWire

Antihypertensives: ARBs at the heart of the market

Published By Datamonitor
27 Mar 2006
ResearchWire
ResearchWire

Antihypertensives: mature pipeline reflects market

Published By Datamonitor
01 Aug 2007
ResearchWire
ResearchWire

Antithrombotic market: novel agents will dampen generic incursion

Published By Datamonitor
15 Jan 2007
ResearchWire
ResearchWire

Antithrombotics: blockbuster potential for novel anticoagulants

Published By Datamonitor
31 May 2007
ResearchWire
ResearchWire

Anxiety disorders: global sales set to slide

Published By Datamonitor
03 May 2006
CommentWire
CommentWire

AP Moller-Maersk: delivering a mixed bag

Shipping company AP Moller-Maersk has released its results for 2006. Although overall revenue increased, profitability collapsed due to its container business unit suffering from over-supply in the industry. While the company forecasted a positive picture for 2007, further diversification may be required.

Published By Datamonitor
30 Mar 2007
CommentWire
CommentWire

APA 2010: Alkermes prepares to enter potentially lucrative opioid dependence market

At this year's American Psychiatric Association meeting, US pharmaceutical company Alkermes presented promising new data for Vivitrol in the treatment of opioid dependence. The FDA is currently assessing the drug under a priority review, and approval in the burgeoning opioid dependence indication would be a major boon for Alkermes.

Published By Datamonitor
10 Jun 2010
Expert View
Expert View

APA 2010: limited data highlight unmet needs in bipolar disorder

Several leading drug makers presented new data in bipolar disorder at this year's meeting of the American Psychiatric Association. Despite Cephalon's Nuvigil showing promise as an adjunct, modest data for antipsychotics from Merck & Co and Pfizer served only to highlight the remaining unmet needs in the treatment of this disease.

Published By Datamonitor
08 Jun 2010
Expert View
Expert View

APA 2010: Merck and Dainippon take center stage to present new schizophrenia therapies

Schizophrenia played a prominent role at this year's American Psychiatric Association Annual Meeting due to the prevailing high level of unmet need. Merck & Co and Dainippon Sumitomo presented data for new drugs which Datamonitor believes represent important additions to the current treatment portfolio. Elsewhere, an interesting lecture predicted a future of personalized schizophrenia treatments.

Published By Datamonitor
08 Jun 2010
Expert View
Expert View

APA 2010: new long-term data confirm potential of depot formulations

Bringing improved patient compliance, depot formulations tackle a crucial unmet need in schizophrenia and the FDA approval of Invega Sustenna and Zyprexa Relprevv represent important steps to improve the transparency of compliance. At this year's American Psychiatric Association meeting, both Johnson & Johnson and Eli Lilly presented data of these depots' long-term efficacy and safety.

Published By Datamonitor
10 Jun 2010

« | ... | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | ... | » »|

No help is available.